Guggenheim initiated coverage of Roivant Sciences with a Buy rating and $17 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ROIV:
- Cantor biotech/biopharma analysts to hold an analyst/industry conference call
- Roivant Sciences call volume above normal and directionally bullish
- Insider Trading: Immunovant Stock (NASDAQ:IMVT) Gains on Director’s Huge Buy
- Roivant Sciences director sells $79.7M in common stock
- Roivant Sciences files $1.5B mixed securities shelf